HER2 Negative ER/PR Positive - Randomized Phase 3 Study of Ipatasertib in Combination with Paclitaxel as a Treatment for Patients with PIK3CA/AKT1/PTEN-Altered Locally Advanced of Metastatic Triple Negative Breast Cancer or Hormone-Receptor Positive, HER2-Negative Breast Cancer

This purpose of this randomized phase 3 trial is to determine if it is more effective to add ipatasertib to paclitaxel in patients  with PIK3CA/AKT1/PTEN-altered locally Advanced of metastatic triple negative breast cancer or hormone-receptor positive, HER2-negative breast cancer